NCT04249713

An Alternative Dose Interval Study in Participants With Hidradenitis Suppurativa Receiving Brodalumab

An Alternative Dose Interval Study to Examine Safety and Identify Potential Biomarkers in Participants With Hidradenitis Suppurativa Receiving Brodalumab

• Status: Withdrawn
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Rockefeller University · Academic / Other
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

Phase 0 Study of an alternative dosing interval of Brodalumab in patients with moderate to severe Hidradenitis Suppurativa to identify biomarkers of disease activity and clinical response.

Detailed description

Phase 0, Open Label study of an alternative dosing interval of Brodalumab in patients with moderate to severe Hidradenitis Suppurativa. Consisting of n=10 patients receiving 210mg subcutaneously every week for 24 weeks. Patients will be followed for a period of 36 weeks (12 weeks after last dose of Brodalumab) to assess for safety.

Conditions

• Hidradenitis Suppurativa

Interventions

Type	Name	Description
DRUG	Brodalumab	Interleukin 17 Receptor A Antagonist

Timeline

• Start date: 2020-02-03
• Primary completion: 2020-07-01
• Completion: 2020-09-01
• First posted: 2020-01-31
• Last updated: 2020-09-04

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study